B cells take the front seat: Dysregulated B cell signals orchestrate loss of tolerance and autoantibody production

Current Opinion in Immunology

Volumn 33, Issue , 2015, Pages 70-77

  Jackson, Shaun W ^a,b   Kolhatkar, Nikita S ^a,b   Rawlings, David J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE ANTIGEN; BANK1 PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; CYTOKINE;

ANTIBODY PRODUCTION; AUTOIMMUNITY; B LYMPHOCYTE; ENZYME DEFICIENCY; GENETIC MANIPULATION; GENETIC VARIABILITY; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYN DEFICIENCY; NONHUMAN; NUCLEAR REPROGRAMMING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; WISKOTT ALDRICH SYNDROME; ANIMAL; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGEN PRESENTATION; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CYTOKINES; GERMINAL CENTER; HUMANS; IMMUNE TOLERANCE; SIGNAL TRANSDUCTION;

EID: 84922424028     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.01.018     Document Type: Review

References (66)

1. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
2. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.
3. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., Kallenberg C.G., St Clair E.W., Turkiewicz A., Tchao N.K., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
4. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
5. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., Li E.K., Thomas M., Kim H.Y., Leon M.G., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
6. Kyogoku C., Langefeld C.D., Ortmann W.A., Lee A., Selby S., Carlton V.E., Chang M., Ramos P., Baechler E.C., Batliwalla F.M., et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004, 75:504-507.
7. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., MacMurray J., Meloni G.F., Lucarelli P., Pellecchia M., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004, 36:337-338.
8. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010, 10:328-343.
9. Zenewicz L.A., Abraham C., Flavell R.A., Cho J.H. Unraveling the genetics of autoimmunity. Cell 2010, 140:791-797.
10. Wellmann U., Letz M., Herrmann M., Angermuller S., Kalden J.R., Winkler T.H. The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci U S A 2005, 102:9258-9263.
11. William J., Euler C., Christensen S., Shlomchik M.J. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002, 297:2066-2070.
12. Vinuesa C.G., Sanz I., Cook M.C. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009, 9:845-857.
13. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6:205-217.
14. Rawlings D.J., Schwartz M.A., Jackson S.W., Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol 2012, 12:282-294.
15. Hou B., Saudan P., Ott G., Wheeler M.L., Ji M., Kuzmich L., Lee L.M., Coffman R.L., Bachmann M.F., DeFranco A.L. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 2011, 34:375-384.
16. Shlomchik M.J. Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol 2009, 21:626-633.
17. Green N.M., Marshak-Rothstein A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 2011, 23:106-112.
18. Sullivan K.E., Mullen C.A., Blaese R.M., Winkelstein J.A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994, 125:876-885.
19. Becker-Herman S., Meyer-Bahlburg A., Schwartz M.A., Jackson S.W., Hudkins K.L., Liu C., Sather B.D., Khim S., Liggitt D., Song W., et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 2011, 208:2033-2042.
20. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., Smyth M.J., Mackay C.R., Mackay F. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007, 204:1959-1971.
21. Ehlers M., Fukuyama H., McGaha T.L., Aderem A., Ravetch J.V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006, 203:553-561.
22. Teichmann L.L., Schenten D., Medzhitov R., Kashgarian M., Shlomchik M.J. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 2013, 38:528-540.
23. Hua Z., Gross A.J., Lamagna C., Ramos-Hernandez N., Scapini P., Ji M., Shao H., Lowell C.A., Hou B., DeFranco A.L. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol 2014, 192:875-885.
24. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005, 202:321-331.
25. Berland R., Fernandez L., Kari E., Han J.H., Lomakin I., Akira S., Wortis H.H., Kearney J.F., Ucci A.A., Imanishi-Kari T. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 2006, 25:429-440.
26. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
27. Lartigue A., Courville P., Auquit I., Francois A., Arnoult C., Tron F., Gilbert D., Musette P. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol 2006, 177:1349-1354.
28. Jackson S.W., Scharping N.E., Kolhatkar N.S., Khim S., Schwartz M.A., Li Q.Z., Hudkins K.L., Alpers C.E., Liggitt D., Rawlings D.J. Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol 2014, 192:4525-4532.
29. Deane J.A., Pisitkun P., Barrett R.S., Feigenbaum L., Town T., Ward J.M., Flavell R.A., Bolland S. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007, 27:801-810.
30. Walsh E.R., Pisitkun P., Voynova E., Deane J.A., Scott B.L., Caspi R.R., Bolland S. Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proc Natl Acad Sci USA 2012, 109:16276-16281.
31. Soni C., Wong E.B., Domeier P.P., Khan T.N., Satoh T., Akira S., Rahman Z.S. B cell-intrinsic TLR7 signaling is essential for the development of spontaneous germinal centers. J Immunol 2014, 193:4400-4414.
32. Sun X., Wiedeman A., Agrawal N., Teal T.H., Tanaka L., Hudkins K.L., Alpers C.E., Bolland S., Buechler M.B., Hamerman J.A., et al. Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol 2013, 190:2536-2543.
33. Shen N., Fu Q., Deng Y., Qian X., Zhao J., Kaufman K.M., Wu Y.L., Yu C.Y., Tang Y., Chen J.Y., et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci USA 2010, 107:15838-15843.
34. Garcia-Ortiz H., Velazquez-Cruz R., Espinosa-Rosales F., Jimenez-Morales S., Baca V., Orozco L. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann Rheum Dis 2010, 69:1861-1865.
35. Kawasaki A., Furukawa H., Kondo Y., Ito S., Hayashi T., Kusaoi M., Matsumoto I., Tohma S., Takasaki Y., Hashimoto H., et al. TLR7 single-nucleotide polymorphisms in the 3' untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res Ther 2011, 13:R41.
36. Han J.W., Zheng H.F., Cui Y., Sun L.D., Ye D.Q., Hu Z., Xu J.H., Cai Z.M., Huang W., Zhao G.P., et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009, 41:1234-1237.
37. Gateva V., Sandling J.K., Hom G., Taylor K.E., Chung S.A., Sun X., Ortmann W., Kosoy R., Ferreira R.C., Nordmark G., et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009, 41:1228-1233.
38. Kobayashi T., Shimabukuro-Demoto S., Yoshida-Sugitani R., Furuyama-Tanaka K., Karyu H., Sugiura Y., Shimizu Y., Hosaka T., Goto M., Kato N., et al. The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity 2014, 41:375-388.
39. Hibbs M.L., Tarlinton D.M., Armes J., Grail D., Hodgson G., Maglitto R., Stacker S.A., Dunn A.R. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995, 83:301-311.
40. Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005, 22:9-18.
41. Lamagna C., Hu Y., DeFranco A.L., Lowell C.A. B cell-specific loss of Lyn kinase leads to autoimmunity. J Immunol 2014, 192:919-928.
42. Harley J.B., Alarcon-Riquelme M.E., Criswell L.A., Jacob C.O., Kimberly R.P., Moser K.L., Tsao B.P., Vyse T.J., Langefeld C.D., Nath S.K., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008, 40:204-210.
43. Hom G., Graham R.R., Modrek B., Taylor K.E., Ortmann W., Garnier S., Lee A.T., Chung S.A., Ferreira R.C., Pant P.V., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008, 358:900-909.
44. Lu R., Vidal G.S., Kelly J.A., Delgado-Vega A.M., Howard X.K., Macwana S.R., Dominguez N., Klein W., Burrell C., Harley I.T., et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun 2009, 10:397-403.
45. Surolia I., Pirnie S.P., Chellappa V., Taylor K.N., Cariappa A., Moya J., Liu H., Bell D.W., Driscoll D.R., Diederichs S., et al. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 2010, 466:243-247.
46. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., Ardlie K.G., Huang Q., Smith A.M., Spoerke J.M., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75:330-337.
47. Dai X., James R.G., Habib T., Singh S., Jackson S., Khim S., Moon R.T., Liggitt D., Wolf-Yadlin A., Buckner J.H., et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest 2013, 123:2024-2036.
48. Zhang J., Zahir N., Jiang Q., Miliotis H., Heyraud S., Meng X., Dong B., Xie G., Qiu F., Hao Z., et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011, 43:902-907.
49. Yokoyama K., Su Ih I.H., Tezuka T., Yasuda T., Mikoshiba K., Tarakhovsky A., Yamamoto T. BANK regulates BCR-induced calcium mobilization by promoting tyrosine phosphorylation of IP(3) receptor. EMBO J 2002, 21:83-92.
50. Aiba Y., Yamazaki T., Okada T., Gotoh K., Sanjo H., Ogata M., Kurosaki T. BANK negatively regulates Akt activation and subsequent B cell responses. Immunity 2006, 24:259-268.
51. Kozyrev S.V., Abelson A.K., Wojcik J., Zaghlool A., Linga Reddy M.V., Sanchez E., Gunnarsson I., Svenungsson E., Sturfelt G., Jonsen A., et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008, 40:211-216.
52. Wong F.S., Wen L., Tang M., Ramanathan M., Visintin I., Daugherty J., Hannum L.G., Janeway C.A., Shlomchik M.J. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 2004, 53:2581-2587.
53. Noorchashm H., Lieu Y.K., Noorchashm N., Rostami S.Y., Greeley S.A., Schlachterman A., Song H.K., Noto L.E., Jevnikar A.M., Barker C.F., et al. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol 1999, 163:743-750.
54. Hulbert C., Riseili B., Rojas M., Thomas J.W. B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J Immunol 2001, 167:5535-5538.
55. Molnarfi N., Schulze-Topphoff U., Weber M.S., Patarroyo J.C., Prod'homme T., Varrin-Doyer M., Shetty A., Linington C., Slavin A.J., Hidalgo J., et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013, 210:2921-2937.
56. Lund F.E. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008, 20:332-338.
57. Bermejo D.A., Jackson S.W., Gorosito-Serran M., Acosta-Rodriguez E.V., Amezcua-Vesely M.C., Sather B.D., Singh A.K., Khim S., Mucci J., Liggitt D., et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol 2013, 14:514-522.
58. Shen P., Roch T., Lampropoulou V., O'Connor R.A., Stervbo U., Hilgenberg E., Ries S., Dang V.D., Jaimes Y., Daridon C., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507:366-370.
59. Dang V.D., Hilgenberg E., Ries S., Shen P., Fillatreau S. From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol 2014, 28:77-83.
60. Sweet R.A., Lee S.K., Vinuesa C.G. Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity. Curr Opin Immunol 2012, 24:658-664.
61. Lee S.K., Silva D.G., Martin J.L., Pratama A., Hu X., Chang P.P., Walters G., Vinuesa C.G. Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 2012, 37:880-892.
62. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., Utset T.O., Gordon C., Isenberg D.A., Hsieh H.J., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
63. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., Maciuca R., Zhang D., Garg J.P., Brunetta P., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226.
64. Rankin A.L., Seth N., Keegan S., Andreyeva T., Cook T.A., Edmonds J., Mathialagan N., Benson M.J., Syed J., Zhan Y., et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol 2013, 191:4540-4550.
65. Honigberg L.A., Smith A.M., Sirisawad M., Verner E., Loury D., Chang B., Li S., Pan Z., Thamm D.H., Miller R.A., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010, 107:13075-13080.
66. Mina-Osorio P., LaStant J., Keirstead N., Whittard T., Ayala J., Stefanova S., Garrido R., Dimaano N., Hilton H., Giron M., et al. Suppression of glomerulonephritis in lupus-prone NZB x NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Arthritis Rheum 2013, 65:2380-2391.